In short: Redensyl is a proprietary cosmetic ingredient blend used in topical hair products. The available human studies tested finished lotions containing Redensyl alongside other active complexes. They offer limited evidence about those complete formulas, rather than proof that Redensyl alone or every serum bearing its name regrows hair.

Redensyl is a proprietary blend supplied as an ingredient for topical cosmetic products. The human studies discussed here tested complete lotions containing Redensyl alongside other active complexes, so they cannot establish what Redensyl would do by itself or predict the result from every serum that lists it.

Two studies provide the main published human evidence considered here. Both ran for 24 weeks in adults with androgenetic alopecia, commonly called pattern hair loss, but they tested different combinations and used different comparators and outcome measures (Katoulis and colleagues, 2020; Karaca and Akpolat, 2019).

What is Redensyl, and why can formulas differ?

Redensyl is the trade name for a multi-component cosmetic raw material. The 2019 paper describes it as a mixture containing two glucoside compounds, glycine and zinc. That description identifies the raw material used by the researchers. It is not a complete specification for every finished bottle sold to consumers (Karaca and Akpolat, 2019).

A manufacturer can put a proprietary raw material into a lotion with solvents, preservatives, fragrances and other named active complexes. The amount used, the rest of the formula and the way the product is made may differ. Sharing the Redensyl name therefore shows that products have an ingredient label in common. It does not show that they reproduce a study formula.

The distinction is visible in the research itself. One study tested a lotion containing Redensyl and another patented formula called Sepicontrol A5. The other tested a specially prepared lotion combining Redensyl, Capixyl and Procapil, which the paper shortens to RCP (Katoulis and colleagues, 2020; Karaca and Akpolat, 2019). Neither study separated Redensyl from the other components. Any observed change belongs to the complete tested formula and study conditions.

Claims about how individual components might act in cells or hair follicles cannot solve this problem. A proposed laboratory mechanism is different from a controlled clinical result in people. These trials can be appraised through the people enrolled, the comparator, the measurements and the follow-up actually reported.

What did the vehicle-controlled study test?

Katoulis and colleagues randomly assigned 44 adults with androgenetic alopecia to an active lotion or its vehicle. A vehicle contains the base of the lotion without the studied active blend, so this design was intended to compare the complete Redensyl and Sepicontrol A5 combination with its base. Forty-one people completed the 24-week study, including 18 men and 23 women (Katoulis and colleagues, 2020).

The researchers assessed participants at the start, 12 weeks and 24 weeks. Their measures included clinical examination, photographs, a hair-cycle measure called the anagen-to-telogen ratio, participant self-assessment and a dermatology quality-of-life questionnaire. The abstract reports improvements within the 26-person active group, including changes in self-assessment, quality of life and the hair-cycle ratio (Katoulis and colleagues, 2020).

The available abstract creates an important reporting limit. It gives detailed changes for the active group but no clear numerical estimate of the difference between active lotion and vehicle for the main reported outcomes. A change from the start of treatment can reflect several influences. The between-group difference is what would help separate the formula’s effect from changes also seen with the vehicle, repeated measurement or the passage of time.

The abstract also gives no basis for assigning the change to Redensyl alone because Sepicontrol A5 was part of the active lotion. It reports that no significant adverse events occurred, but 41 completers over 24 weeks cannot establish safety across larger populations, other formulations or longer use (Katoulis and colleagues, 2020). The PubMed record contains the abstract, rather than the complete methods and results needed to examine allocation, missing data and all between-group analyses in detail.

What can the three-complex formula study establish?

Karaca and Akpolat enrolled 120 men aged 18 to 55 with specified stages of androgenetic alopecia. The study randomly allocated them to the RCP lotion or topical minoxidil as an active comparator, and 106 completed 24 weeks. It described itself as prospective and open-ended, meaning participants and researchers were not reported as blinded to the assigned product (Karaca and Akpolat, 2019).

The researchers used their own rating of hair growth and scalp coverage as the primary measure. They also used global photographs and participant questionnaires. Those methods assess visible or perceived change, but an open study is more exposed to expectation and observer effects than a blinded assessment. The paper did not test Redensyl against an otherwise identical formula without Redensyl. Capixyl and Procapil remained in the same lotion throughout, so the study cannot identify which complex contributed to any result.

There are also reporting inconsistencies. The prose says 68 participants returned the self-scoring questionnaire, split equally between groups. The accompanying questionnaire tables total 70 responses, with 36 in the RCP group and 34 in the comparator group. That mismatch makes the self-reported results harder to interpret. The paper’s photographs and rating categories also differ from a direct measurement of hair count or shaft diameter (Karaca and Akpolat, 2019).

The study is useful as evidence that one specific three-complex lotion was evaluated in adult men for 24 weeks. Its design cannot support promotional percentages as an individual’s chance of success, prove that RCP is equivalent to Redensyl alone or show how an unrelated retail serum will perform. It also provides no post-treatment follow-up showing whether observed changes persisted.

What do the findings mean for a serum labelled Redensyl?

A result from either paper applies most directly to the exact finished lotion, population, outcome and 24-week period studied. The first formula combined Redensyl with Sepicontrol A5 and included men and women. The second combined Redensyl with Capixyl and Procapil and included men only. One used a vehicle control and the other an active comparator (Katoulis and colleagues, 2020; Karaca and Akpolat, 2019).

The endpoints need equally careful reading. A better participant rating describes what a participant reported, while a photograph score records a researcher’s judgement under that study’s scale. Changes in the proportion of hairs in growth and resting phases are measured hair-cycle outcomes. None directly demonstrates the creation of new follicles, permanent restoration or a predictable cosmetic result for another person.

These studies concerned adults diagnosed with androgenetic alopecia. Hair loss can also be temporary or related to illness, stress, weight loss or iron deficiency, among other causes listed by the NHS. Evidence from a pattern-hair-loss trial should not be transferred to every type of shedding or thinning. The NHS advises seeing a GP to get an idea of the cause before approaching a commercial hair clinic (NHS: Hair loss).

A useful product-evidence check starts with the full ingredient list and the exact finished formula named in the research. Then check whether the study population matches the claimed use, whether the comparison was against a vehicle or another active product, and whether the outcome was an objective count, a photograph rating or a personal score. A shared trademark on the label cannot fill gaps in those details.

Risks and what can go wrong

Short trials with small groups can miss uncommon reactions and delayed problems. The vehicle-controlled abstract reports no significant adverse events, while the RCP paper reports no serious adverse effects in its study. Those statements describe what researchers recorded in two particular 24-week trials. They do not prove that every Redensyl-containing product has the same safety profile (Katoulis and colleagues, 2020; Karaca and Akpolat, 2019).

A finished cosmetic may contain preservatives, fragrances and other ingredients as well as the named blend. The NHS explains that cosmetic ingredients can cause allergic contact dermatitis and that perfumes and preservatives can act as irritants. This is general cosmetic safety context, not a Redensyl-specific reaction rate (NHS: Contact dermatitis causes).

Assuming a cosmetic serum addresses every cause of hair loss can also delay assessment. If hair loss worries you, the NHS route is to see a GP, who may be able to identify the cause by examining your hair and discuss available treatment routes (NHS: Hair loss).

Questions to ask the clinic

Talk it through

If your hair loss has been medically assessed and you want to discuss restoration surgery, GetHair can arrange a free consultation with a partner clinic. The clinic assesses suitability and makes any clinical decisions.

Sources